| Recruiting | Registry Platform Myelofibrosis and Anemia Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | — | 2026-02-19 |
| Recruiting | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma Glioma | — | 2025-12-08 |
| Recruiting | Fruquintinib in Patients With Metastatic Colorectal Cancer Metastatic Colorectal Cancer (mCRC) | — | 2025-02-17 |
| Recruiting | Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly Polycythemia Vera | — | 2024-12-03 |
| Completed | Ripretinib (QINLOCK®) According to Current SmPC GIST - Gastrointestinal Stromal Tumor | — | 2024-10-17 |
| Recruiting | Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Pri Cholangiocarcinoma | — | 2024-10-08 |
| Completed | Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC Acute Myeloid Leukemia (AML) | — | 2023-12-20 |
| Recruiting | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) | — | 2023-09-27 |
| Active Not Recruiting | Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma | — | 2023-06-28 |
| Active Not Recruiting | Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) CLL | — | 2022-10-12 |
| Completed | Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Tr Multiple Myeloma, Newly Diagnosed, Transplant Ineligible | — | 2022-07-06 |
| Completed | Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Tw HER2-positive Breast Cancer | — | 2022-05-21 |
| Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lym Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma | — | 2022-04-26 |
| Recruiting | Registry Platform Ovarian and Endometrial Cancer Ovarian Cancer, Endometrial Cancer, Ovary Neoplasm | — | 2021-11-25 |
| Active Not Recruiting | Registry Platform Colorectal Cancer Colorectal Cancer Metastatic | — | 2021-05-01 |
| Completed | Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusi NTRK Family Gene Mutation | — | 2020-12-02 |
| Recruiting | Liver Cancer Registry Platform Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | — | 2020-08-09 |
| Completed | Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology Advanced Solid Tumors or Hematologic Malignancies | — | 2020-04-17 |
| Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | — | 2019-12-04 |
| Completed | Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Ad Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer, Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC | — | 2019-07-10 |
| Withdrawn | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Advanced Breast Cancer, HER2-positive Breast Cancer | Phase 3 | 2019-01-01 |
| Completed | Patient Preference for Pegfilgrastim (Neulasta®) Application Forms Non Hodgkin Lymphoma, Breast Cancer | N/A | 2018-06-25 |
| Completed | Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in F Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer | Phase 3 | 2018-05-24 |
| Active Not Recruiting | Breast Cancer Registry Platform Breast Cancer | — | 2017-12-22 |
| Recruiting | Registry Platform Urologic Cancer Renal Cell Carcinoma, Urothelial Carcinoma | — | 2017-12-07 |
| Recruiting | Myeloma Registry Platform (MYRIAM) Multiple Myeloma | — | 2017-09-25 |
| Completed | Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOL Metastatic Colorectal Cancer, RAS Wild-type | — | 2017-01-25 |
| Completed | Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone o Multiple Myeloma in Relapse | — | 2016-10-25 |
| Completed | Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | 2016-09-06 |
| Completed | Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC Carcinoma, Non-Small-Cell Lung | — | 2016-08-29 |
| Completed | Patient Reported Outcomes Registry in Patient With Cancer Cachexia Metastatic Pancreatic Cancer, NSCLC, Metastatic | — | 2016-08-28 |
| Completed | Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma Renal Cell Carcinoma | — | 2015-08-19 |
| Completed | Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myelo Multiple Myeloma | — | 2015-06-23 |
| Completed | Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer Breast Cancer, Prostate Cancer, Bone Metastases | — | 2014-12-23 |
| Completed | Bone Pain Score Validation Initiative Bone Metastasis | — | 2014-12-01 |
| Completed | Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizum Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 4 | 2014-08-01 |
| Completed | Non-interventional Study With Pomalidomide (Imnovid®) Multiple Myeloma | — | 2014-02-11 |
| Completed | Tumor Registry Pancreatic Cancer Pancreas Cancer | — | 2013-12-01 |
| Completed | Non-interventional Study With Nab-Paclitaxel (Abraxane®) Metastatic Breast Cancer | — | 2012-04-01 |
| Completed | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma | Phase 4 | 2012-01-24 |
| Completed | Clinical Tumor Anemia Registry (TAR) Anemia | — | 2011-12-01 |
| Completed | Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failur Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy | Phase 4 | 2011-03-01 |
| Completed | Non-interventional Study With Azacitidin (Vidaza®) MDS, AML, CMMOL | — | 2010-07-01 |
| Completed | Tumour Registry Lung Cancer (TLK) Lung Cancer | — | 2010-01-01 |
| Completed | Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexame Multiple Myeloma | — | 2009-05-01 |
| Completed | Tumor Registry of Lymphatic Neoplasia Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) | — | 2009-04-01 |
| Completed | Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer Metastatic Breast Cancer | Phase 3 | 2009-02-01 |
| Completed | Epidemiological EMESIS-Registry Antiemetic Therapy | — | 2008-10-01 |
| Completed | Tumor Registry of Advanced Renal Cell Carcinoma Renal Cell Carcinoma | — | 2007-12-01 |
| Completed | Tumour Registry Breast Cancer Breast Cancer | — | 2007-02-01 |
| Completed | Tumour Registry Colorectal Cancer Colorectal Cancer | — | 2006-09-01 |